Research programme - T cell receptor-based cancer therapeutics - Bellicum Pharmaceuticals/Leiden University Medical Center

Drug Profile

Research programme - T cell receptor-based cancer therapeutics - Bellicum Pharmaceuticals/Leiden University Medical Center

Alternative Names: High-affinity T cell receptor product candidates - Bellicum Pharmaceuticals/LUMC; TCR cell therapies - Bellicum Pharmaceuticals/LUMC; TCRs - Bellicum Pharmaceuticals/Leiden University Medical Center

Latest Information Update: 09 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bellicum Pharmaceuticals; Leiden University Medical Center
  • Developer Leiden University Medical Center
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 02 Jun 2016 Bellicum Pharmaceuticals and Leiden University Medical Center agree to co-develop T cell receptor-based therapeutics in Netherlands for Cancer
  • 02 Jun 2016 Early research in Cancer in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top